Related Experiment Video
Updated: Apr 27, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Using proteomics to unravel the mysterious steps of the HBV-life-cycle
Norica Branza-Nichita1, Catalina Petrareanu, Catalin Lazar
1Department of Viral Glycoproteins, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei, 296, Sector 6, Bucharest, 060031, Romania, nichita@biochim.ro.
Insights
Hepatitis B virus (HBV) infection causes chronic liver disease and hepatocellular carcinoma (HCC). Proteomics advances enhance understanding of HBV pathogenesis, aiding new biomarker discovery for early diagnosis and treatment.
Area of Science:
- Hepatology and Viral Hepatitis Research
- Proteomics and Biomarker Discovery
- Cancer Pathogenesis and Carcinogenesis
Background:
- Hepatitis B virus (HBV) infection is a leading global cause of liver disease, often progressing to chronic conditions.
- Chronic HBV infection can lead to severe liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
- Hepatocellular carcinoma (HCC) is a rapidly fatal cancer with limited treatment success, largely due to late diagnosis and inadequate screening.
Purpose of the Study:
- To critically review the impact of proteomic studies on understanding HBV-associated pathogenesis.
- To explore the role of proteomics in identifying new biomarkers for prognostic and early diagnosis of HBV-related liver disease.
- To assess how proteomic advancements contribute to developing novel therapeutic strategies for HBV infection and HCC.
Main Methods:
- Review of recent scientific literature focusing on proteomic investigations in HBV infection.
- Analysis of technical improvements in proteomics, including quantification accuracy, sensitivity, and large-scale analysis of low-abundant proteins.
- Evaluation of proteomic data derived from clinical samples for relevance to HBV pathogenesis and diagnostics.
Main Results:
- Proteomics has significantly advanced the understanding of complex HBV-host cell interactions.
- Recent proteomic techniques enable large-scale analysis of low-abundance proteins, crucial for early disease detection.
- Proteomic studies are pivotal in identifying potential biomarkers for HBV progression and HCC development.
Conclusions:
- Proteomic studies are indispensable for unraveling HBV pathogenesis and identifying diagnostic/prognostic biomarkers.
- Continued advancements in proteomics offer promising avenues for improved early diagnosis and targeted treatment of HBV-related liver diseases.
- Integrating proteomic findings into clinical practice is essential for combating the global burden of HBV and HCC.
Abstract:
Infection with Hepatitis B virus (HBV) is the most common cause of liver disease in the world. Infection becomes chronic in up to 10 % of adults, with severe consequences on liver function, including inflammation, fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). HCC is a fast progressing disease causing the death of approximately one million patients annually; current treatment has very limited success, mainly due to late-stage diagnosis and poor screening methodologies. Therefore, unraveling the complex HBV-host cell interactions during progression of the disease is of crucial importance, not only to understand the mechanisms underlying carcinogenesis, but importantly, for the development of new biomarkers for prognostic and early diagnosis. This is an area of research strongly influenced by proteomic studies, which have benefited in the last decade from major technical improvements in accuracy of quantification and sensitivity, large-scale analysis of low-abundant proteins, such as those from clinical samples being now possible and widely applied. This work is a critical review of the impact of the proteomic studies on our current understanding of HBV-associated pathogenesis, diagnostics, and treatment.
Related Concept Videos
Hepatitis
Viruses with RNA Genomes
Retrovirus Life Cycles
Viral Hepatitis I: Introduction

